Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger

Annals of Surgery

Volumn 224, Issue 3, 1996, Pages 255-266

  Balch, Charles M ^a,j   Soong, Seng Jaw ^a   Bartolucci, Alfred A ^b   Urist, Marshall M ^c   Karakousis, Constantine P ^d   Smith, Thomas J ^e   Temple, Walley J ^f   Ross, Merrick I ^g   Jewell, William R ^h   Mihm Jr , Martin C ⁱ   Barnhill, Raymond L ^a   Wanebo, Harold J ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF KANSAS   (United States)

^d Medical Center   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f MORRISTOWN MEMORIAL HOSPITAL   (United States)

^g TOM BAKER CANCER CENTRE   (Canada)

^h ALBANY MEDICAL CENTER   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j BROWN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; MULTICENTER STUDY; PATIENT SELECTION; PRIORITY JOURNAL; SKIN ULCER; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VOLUME;

FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SURVIVAL RATE;

EID: 0006690138     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199609000-00002     Document Type: Conference Paper

References (15)

1. Balch CM, Milton GW, Cascinelli N, Sim FH.,Elective lymph node dissection: pros and cons. In: Balch CM, Houghton A, Milton GW, et al, eds. Cutaneous Melanoma. 2nd ed. Philadelphia, PA: JB Lippincott; 1992:345-366.
2. Milton GW, Shaw HH, McCarthy WJ, et al. Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1,319 patients. Br J Surg 1982; 69: 108-111.
3. Coates AS, Ingvar CI, Petersen-Schaefer K, et al. Elective lymph node dissection in patients with primary melanoma of the trunk and limbs treated at the Sydney melanoma unit from 1960 to 1991. J Am Coll Surg 1995; 180:402-409.
4. Veronesi U. Efficacy of immediate node dissection of stage II melanoma: N EnglJ Med 1977; 2:627-630.
5. Veronesi U, Adamus J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982; 49:2420-2430.
6. Sim FH, Taylor WF, Ivins JC, et'al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Cancer 1978; 41:948-956.
7. Balch CM, Murad TM, Soong S-j, et al. A multifactorial analysis of melanoma: I, prognostic histological features comparing Clark's and Breslow's staging methods. Ann Surg 1978; 188:732-742.
8. Balch CM, Murad TM, Soong S-j, et al. Tumor thickness as a guide to surgical management of clinical stage I melanoma patients. Cancer 1979; 43:883-888.
9. Balch CM, Soong S-j, Murad R, et al. A multifactorial analysis of melanoma: II, prognostic factors in patients with stage I (localized) melanoma. Surgery 1979; 86:343-351.
10. Balch CM, Soong S-j, Milton GW, et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg 1982; 196:577-684.
11. Zelen M. A new design for randomized clinical trials. N Engl J Med 1979; 300:1242-1245.
12. Austin PF, Cruse CW, Lyman G, et al. Age as a prognostic factor in the malignant melanoma population Ann Surg Oncol 1994; 6: 487-494.
13. Morton DL, Wen DR, Wong JM, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392-399.
14. Reintgen D, Cruse CW, Wells K, et al. The orderly progresssion of melanoma nodal métastases. Ann Surg 1994; 220:759-767.
15. Kirkwood JM, Strawderman MH, ErnstofTMs, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern cooperative oncology group trial EST 1684. J Clin Oncol 1996; 14:7-17.